Pamela Savoy Added as Director of Business Development at Coldstream Laboratories, Inc.
Christopher A. Verbicky, Ph.D., MBA, will be attending the “6th Product and Pipeline Enhancement for Generics Conference” in this week in Washington, D.C. The event will take place at the Sheraton Crystal City Hotel July 23 – 25, 2013.
Plantation, Florida and Lexington, Kentucky-- Goodwin Biotechnology, Inc. (GBI) and Coldstream Laboratories, Inc. have established a collaboration for developing and manufacturing high-potency, highly cytotoxic materials (e.g., small molecules, protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates).
Photo Caption: Equinext’s President and CEO, Eric Hauck, with Eric Smart, President and CEO of Coldstream Laboratories in Coldstream’s sterile manufacturing facility.
Representatives from Coldstream Laboratories will be attending Informex 2013 in Anaheim, CA. The event will take place at the Anaheim Convention Center February 19 - 22, 2013.
LEXINGTON, KY (Marketwire - October 29, 2012) – Eric W. Smart has been named the new President and CEO of Coldstream Laboratories Inc., the largest sterile pharmaceutical manufacturing facility in Kentucky.
In April of 2012, Coldstream Laboratories expanded its sales presence to the West Coast with the addition of Heidi Kipers as Business Development Manager. As Coldstream’s West Coast sales representative, Heidi is based in San Diego, CA, and represents the territory west of the Rocky Mountains.
The sterile manufacturing facility at Coldstream Laboratories employs unique mobile isolator technology to allow flexibility in executing a wide variety of manufacturing processes. Our isolators facilitate handling of difficult-to-manufacture drug products and ensure the safety of our workforce throughout the production process. Mobile isolators provide an ISO Class 5 environment for aseptic processing and minimize human contact with the products we manufacture. This technology allows Coldstream to process a variety of potent drug substances such as cytotoxins in an adaptable alternative manufacturing setting when compared to standard clean rooms.